Home › Research › Treatments
Mouse models for studying anti‐amyloid antibody‐induced ARIA
Cynthia Ann Lemere. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Thus far, studies of ARIA in amyloid mouse models have focused mainly on the development of microhemorrhages (ARIA-H) following chronic immunization. However, MRIs and measures of BBB leakiness and RBC extravasation are now used to monitor the very early effects of anti-amyloid immunotherapy in mouse brain. Recruitment of immune cells to the brain vasculature, activation of the classical complement cascade, and attempts at vascular remodeling in response to anti-amyloid antibodies have been demonstrated in mice. Various -omics studies suggest potential biomarkers. Take together, studies of anti-amyloid antibody-induced ARIA in amyloid mouse models have provided insight into the mechanisms underlying ARIA. These models can be used to both identify therapeutic targets and test drugs for efficacy in mitigating ARIA that may be translated into human clinical studies. FUNDING: NIH NIA 1R01AG084531, NINDS 1R01NS136122-01 and Cure Alzheimer Fund (CAL).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lemere, C. A. (2025). Mouse models for studying anti‐amyloid antibody‐induced ARIA. Alzheimer s & Dementia. https://doi.org/10.1002/alz70861_108865
Vancouver
Lemere CA. Mouse models for studying anti‐amyloid antibody‐induced ARIA. Alzheimer s & Dementia. 2025. doi:10.1002/alz70861_108865. PMID: 41434072.
BibTeX
@article{lemere2025-41434072,
author = {Lemere, Cynthia Ann},
title = {{Mouse models for studying anti‐amyloid antibody‐induced ARIA}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70861_108865},
pmid = {41434072},
url = {https://doi.org/10.1002/alz70861_108865}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Thus far, studies of ARIA in amyloid mouse models have focused mainly on the development of microhemorrhages (ARIA-H) following chronic immunization.
- However, MRIs and measures of BBB leakiness and RBC extravasation are now used to monitor the very early effects of anti-amyloid immunotherapy in mouse brain.
- Recruitment of immune cells to the brain vasculature, activation of the classical complement cascade, and attempts at vascular remodeling in response to anti-amyloid antibodies have been demonstrated in mice.
- Various -omics studies suggest potential biomarkers.
- Take together, studies of anti-amyloid antibody-induced ARIA in amyloid mouse models have provided insight into the mechanisms underlying ARIA.
Why it matters
Studies in amyloid mouse models have provided insight into the mechanisms underlying ARIA, including immune cell recruitment to brain vasculature and activation of the classical complement cascade. These models can be used to identify therapeutic targets and test drugs for mitigating ARIA, but the findings are from animals and may not translate directly to humans.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Cynthia Ann Lemere: h-index 67 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41434072) |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70861_108865
- PubMed: 41434072
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.